Lumida
/DNTH
⌘K
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc

DNTH
$106.20USD+2.83%+2.92 today

MARKET CAP

5.9B

P/E (TTM)

FWD P/E

DAY RANGE

$105 – $110

52W RANGE

$32
$118

AI Summary

Stalk
Sell NowMedium

DNTH is in Stage 3 distribution with price below its 50-day SMA and short EMAs, consistent with the active Bearish Pivot Point pattern signaling structural repair lower. The medium-term bias is bearish, and short-term execution readiness is confirmed by price extension and rejection below the 9/20 EMAs. Executing Sell Now into rallies back toward the 9/20 EMA and 50-day SMA resistance aligns with the prevailing downward momentum and pattern implications.

  • DNTH312 bifunctional fusion protein targets complex autoimmune disorders, IP through 2047.
  • Reached 52-week high at $114.60 with average target of $124.27.
  • Q2 2026 net loss of $50.22M with zero revenue, cash burn ongoing.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$2.8M$6.2M$2.0M
YoY %+120.6%-67.3%
P / Sales20.9x116.5x781.6x
EV / Sales-22.2x116.3x775.0x
Gross Profit, Adj.$2.8M$6.2M$2.0M
YoY %+120.6%-67.3%
Margin %100.0%100.0%100.0%
EV / Gross Profit-22.2x116.3x775.0x
EBITDA, Adj.$-48.1M$-101.8M$-177.8M
YoY %-111.5%-74.7%
Margin %-1702.3%-1632.2%-8733.9%
EV / EBITDA1.3x-7.1x-8.9x
EBIT$-48.2M$-101.9M$-177.9M
YoY %-111.5%-74.7%
Margin %-1704.7%-1633.7%-8739.3%
EV / EBIT1.3x-7.1x-8.9x
Net Income$-43.6M$-85.0M$-162.3M
YoY %-95.1%-91.1%
Net Margin-1541.2%-1362.8%-7973.3%
EPS (GAAP)-$8.45-$2.55-$4.20
YoY %+69.8%-64.7%